Thank you Renae for starting the discussion! My name is Ram Venkateswaran and I am an MS3 from Harvard Medical School. I too am excited to help moderate this discussion, especially at a time when cholesterol management is in the public limelight and heart disease continues to be a major health concern.
The study design is elegant and simple, and raises some very important questions that have big implications, including the LDL vs. statin hypothesis which you have already started discussing.
With regards to the statin hypothesis, how exactly do you think ezetimibe works to reduce adverse CV outcomes when added to statin monotherapy? Is there something unique to its mechanism of action that distinguishes it from its other lipid-lowering counterparts which have failed to show significant risk reduction in similar trials?